Welcome to the Newron Pharmaceuticals website.
We are a clinical-stage biopharmaceutical company. Our shares are listed on the SWX Swiss Exchange (NWRN). Our mission is to discover, develop and commercialise novel drugs to treat diseases of the Central Nervous System (CNS) and pain.
Discovering and developing innovative therapeutics for CNS disorders
Research & Drug Development
1998
Maj R.; Fariello R.G.; Ukmar G.; Varasi M.; Pevarello P.; McArthur R.A.;Salvati P.
PNU-151774E Protects Against Kainate-Induced Status Epilepticus and Hippocampal Lesions in the Rat.
Eur.; J. Pharmacol.; 359: 27-32, 1998
Pevarello P.; Bonsignori A.; Dostert P.; Heidempergher F., Pinciroli V.; Colombo M.; McArthur R.A.; Salvati P.; Fariello R.G.; Varasi M.
Synthesis and Anticonvulsant Activity of a New Class of 2-((Arylalkyl) Amino) Alkamide Derivatives.
J. Med. Chem.; 41: 579-590, 1998
Fariello R.G.; McArthur R.A.; Bonsignori A.; Cervini M.A.; Maj R.; Marrari P.; Pevarello P.; Wolf H.H.; Woodhead J.W.; White H.S.; Varasi M.; Salvati P.; Post C.
Preclinical Evaluation pf PNU-151774E as a Novel Anticonvulsant
J. Pharmac.Exp. Ther. 285: 397-403, 1998